JPWO2022183101A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022183101A5 JPWO2022183101A5 JP2023551180A JP2023551180A JPWO2022183101A5 JP WO2022183101 A5 JPWO2022183101 A5 JP WO2022183101A5 JP 2023551180 A JP2023551180 A JP 2023551180A JP 2023551180 A JP2023551180 A JP 2023551180A JP WO2022183101 A5 JPWO2022183101 A5 JP WO2022183101A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell
- car
- sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 7
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 7
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 7
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 7
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 201000005787 hematologic cancer Diseases 0.000 claims 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163154618P | 2021-02-26 | 2021-02-26 | |
| US63/154,618 | 2021-02-26 | ||
| PCT/US2022/018117 WO2022183101A1 (en) | 2021-02-26 | 2022-02-28 | Anti-muc1-c antibodies and car-t structures |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024508808A JP2024508808A (ja) | 2024-02-28 |
| JPWO2022183101A5 true JPWO2022183101A5 (https=) | 2025-03-07 |
| JP2024508808A5 JP2024508808A5 (https=) | 2025-03-07 |
Family
ID=80780549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023551180A Pending JP2024508808A (ja) | 2021-02-26 | 2022-02-28 | 抗ｍｕｃ１－ｃ抗体及びｃａｒ－ｔ構造 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240182597A1 (https=) |
| EP (1) | EP4298129A1 (https=) |
| JP (1) | JP2024508808A (https=) |
| KR (1) | KR20230150825A (https=) |
| CN (1) | CN116917327A (https=) |
| AU (1) | AU2022226565A1 (https=) |
| CA (1) | CA3211142A1 (https=) |
| MX (1) | MX2023009882A (https=) |
| WO (1) | WO2022183101A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| WO2025218621A1 (zh) * | 2024-04-15 | 2025-10-23 | 原启生物科技(上海)有限责任公司 | 靶向muc1的抗原结合蛋白 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US10059775B2 (en) * | 2014-01-29 | 2018-08-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| MX2019000641A (es) * | 2016-07-15 | 2019-06-10 | Poseida Therapeutics Inc | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. |
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| CA3162246A1 (en) * | 2019-12-20 | 2021-06-24 | Poseida Therapeutics, Inc. | Anti-muc1 compositions and methods of use |
-
2022
- 2022-02-28 WO PCT/US2022/018117 patent/WO2022183101A1/en not_active Ceased
- 2022-02-28 MX MX2023009882A patent/MX2023009882A/es unknown
- 2022-02-28 AU AU2022226565A patent/AU2022226565A1/en active Pending
- 2022-02-28 US US18/547,663 patent/US20240182597A1/en active Pending
- 2022-02-28 CN CN202280016735.6A patent/CN116917327A/zh active Pending
- 2022-02-28 EP EP22710882.6A patent/EP4298129A1/en active Pending
- 2022-02-28 CA CA3211142A patent/CA3211142A1/en active Pending
- 2022-02-28 KR KR1020237031883A patent/KR20230150825A/ko active Pending
- 2022-02-28 JP JP2023551180A patent/JP2024508808A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103687879B (zh) | 多价抗原结合fv分子 | |
| CN102239182B (zh) | Muc1*抗体 | |
| KR101477762B1 (ko) | 특이성 결합 단백질 및 용도 | |
| JP2018502050A5 (https=) | ||
| JP2023100903A (ja) | 多価メディトープ、メディトープ結合性抗体およびそれらの使用 | |
| JP2021530236A5 (https=) | ||
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2021522162A5 (https=) | ||
| CN113330034A (zh) | 针对B7-H3的IgV结构域的单克隆抗体及其用途 | |
| JP2020529864A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| TW202035440A (zh) | 新穎合理設計的蛋白質組合物 | |
| JPWO2020018922A5 (https=) | ||
| JP2020502233A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| JP2024026820A (ja) | 医薬組成物、その製造方法及び用途 | |
| EP4069312A1 (en) | Compositions and methods for reducing off-target toxicity of antibody drug conjugates | |
| JP2026510999A (ja) | Ｃｄ１９／ｃｄ３８多重特異性抗体 | |
| WO2022194201A1 (zh) | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 | |
| CN114786720B (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JPWO2022183101A5 (https=) | ||
| JPWO2020087065A5 (https=) | ||
| JPWO2022183074A5 (https=) | ||
| JPWO2023078113A5 (https=) | ||
| EP4613770A1 (en) | Antibody binding to cd22, and bispecific antibody, chimeric antigen receptor and antibody-drug conjugate comprising same, and use thereof |